BR-cpd7

• UNSPSC Description:

  BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))[1]

• Target Antigen:

  FGFR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/br-cpd7.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=CC(OC)=C(C(NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)C5CCN(CC5)C(CNC6=CC=CC7=C6C(N(C7=O)C8CCC(NC8=O)=O)=O)=O)=NC=N2)C)=O)=C1Cl)Cl

• Molecular Weight:

  928.82

• References & Citations:

  [1]Kong Y, et al., A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity. Mol Cancer Ther. 2024 Jun 10:OF1-OF11.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported